Search

Your search keyword '"Vanderschueren, Dirk"' showing total 20 results
Start Over Author "Vanderschueren, Dirk" Journal journal of bone and mineral research
20 results on '"Vanderschueren, Dirk"'

1. Testosterone Restores Body Composition, Bone Mass, and Bone Strength Following Early Puberty Suppression in a Mouse Model Mimicking the Clinical Strategy in Trans Boys

Author

Dubois, Vanessa, primary, Ciancia, Silvia, additional, Doms, Stefanie, additional, El Kharraz, Sarah, additional, Sommers, Vera, additional, Kim, Na Ri, additional, David, Karel, additional, Van Dijck, Jolien, additional, Valle-Tenney, Roger, additional, Maes, Christa, additional, Antonio, Leen, additional, Decallonne, Brigitte, additional, Carmeliet, Geert, additional, Claessens, Frank, additional, Cools, Martine, additional, and Vanderschueren, Dirk, additional

Published
2023
Full Text
View/download PDF

2. Associations of 25‐Hydroxyvitamin D and 1,25‐Dihydroxyvitamin D With Bone Mineral Density, Bone Mineral Density Change, and Incident Nonvertebral Fracture

Author

Swanson, Christine M, Srikanth, Priya, Lee, Christine G, Cummings, Steven R, Jans, Ivo, Cauley, Jane A, Bouillon, Roger, Vanderschueren, Dirk, Orwoll, Eric S, Nielson, Carrie M, and Group, for the Osteoporotic Fractures in Men MrOS Study Research

Subjects
Physical Injury - Accidents and Adverse Effects, Aging, Prevention, Nutrition, Osteoporosis, Musculoskeletal, Aged, Aged, 80 and over, Bone Density, Follow-Up Studies, Hip Fractures, Humans, Incidence, Male, Radiography, Risk Factors, Vitamin D, Osteoporotic Fractures in Men MrOS Study Research Group, 1, 25-DIHYDROXYVITAMIN D, 25-HYDROXYVITAMIN D, BONE MINERAL DENSITY, CALCITRIOL, FRACTURE, Biological Sciences, Engineering, Medical and Health Sciences, Anatomy & Morphology
Abstract

Relationships between 1,25-dihydroxyvitamin D (1,25(OH)2 D) and skeletal outcomes are uncertain. We examined the associations of 1,25(OH)2 D with bone mineral density (BMD), BMD change, and incident non-vertebral fractures in a cohort of older men and compared them with those of 25-hydroxyvitamin D (25OHD). The study population included 1000 men (aged 74.6 ± 6.2 years) in the Osteoporotic Fractures in Men (MrOS) study, of which 537 men had longitudinal dual-energy X-ray absorptiometry (DXA) data (4.5 years of follow-up). A case-cohort design and Cox proportional hazards models were used to test the association between vitamin D metabolite levels and incident nonvertebral and hip fractures. Linear regression models were used to estimate the association between vitamin D measures and baseline BMD and BMD change. Interactions between 25OHD and 1,25(OH)2 D were tested for each outcome. Over an average follow-up of 5.1 years, 432 men experienced incident nonvertebral fractures, including 81 hip fractures. Higher 25OHD was associated with higher baseline BMD, slower BMD loss, and lower hip fracture risk. Conversely, men with higher 1,25(OH)2 D had lower baseline BMD. 1,25(OH)2 D was not associated with BMD loss or nonvertebral fracture. Compared with higher levels of calcitriol, the risk of hip fracture was higher in men with the lowest 1,25(OH)2 D levels (8.70 to 51.60 pg/mL) after adjustment for baseline hip BMD (hazard ratio [HR] = 1.99, 95% confidence interval [CI] 1.19-3.33). Adjustment of 1,25(OH)2 D data for 25OHD (and vice versa) had little effect on the associations observed but did attenuate the hip fracture association of both vitamin D metabolites. In older men, higher 1,25(OH)2 D was associated with lower baseline BMD but was not related to the rate of bone loss or nonvertebral fracture risk. However, with BMD adjustment, a protective association for hip fracture was found with higher 1,25(OH)2 D. The associations of 25OHD with skeletal outcomes were generally stronger than those for 1,25(OH)2 D. These results do not support the hypothesis that measures of 1,25(OH)2 D improve the ability to predict adverse skeletal outcomes when 25OHD measures are available. © 2015 American Society for Bone and Mineral Research.

Published
2015

3. Time to onset of antifracture efficacy and year‐by‐year persistence of effect of zoledronic acid in women with osteoporosis

Author

Boonen, Steven, Eastell, Richard, Su, Guoqin, Mesenbrink, Peter, Cosman, Felicia, Cauley, Jane A, Reid, Ian R, Claessens, Frank, Vanderschueren, Dirk, Lyles, Kenneth W, and Black, Dennis M

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Osteoporosis, Aging, Clinical Trials and Supportive Activities, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Aged, Aged, 80 and over, Algorithms, Bone Density, Bone Density Conservation Agents, Diphosphonates, Double-Blind Method, Female, Humans, Imidazoles, Osteoporosis, Postmenopausal, Osteoporotic Fractures, Placebos, Proportional Hazards Models, Risk, Time Factors, Zoledronic Acid, FRACTURES, POSTMENOPAUSAL OSTEOPOROSIS, REACTION TIME, ZOLEDRONIC ACID, BONE MINERAL DENSITY, Biological Sciences, Engineering, Medical and Health Sciences, Anatomy & Morphology, Biological sciences, Biomedical and clinical sciences
Abstract

Oral bisphosphonates reduce fracture risk in osteoporotic patients but are often associated with poor compliance, which may impair their antifracture effects. This post hoc analysis assessed the time to onset and persistence of the antifracture effect of zoledronic acid, a once-yearly bisphosphonate infusion, in women with osteoporosis. Data from 9355 women who were randomized in two placebo-controlled pivotal trials were included. Endpoints included reduction in the rate of any clinical fracture at 6, 12, 18, 24, and 36 months in the zoledronic acid group compared with placebo, and the year-by-year incidence of all clinical fractures over 3 years. Cox proportional hazards regression was used to determine the timing of onset of antifracture efficacy. A generalized estimating equation model was used to assess fracture reduction for the 3 consecutive years of treatment, thereby evaluating persistence of effect. Safety results from women in the two studies were collated. Zoledronic acid reduced the risk of all clinical fractures at 12 months (hazard ratio [HR] = 0.75, 95% confidence interval [CI] 0.61-0.92, p = 0.0050) with significant reductions maintained at all subsequent time points. Year-by-year analysis showed that zoledronic acid reduced the risk for all clinical fractures compared with the placebo group in each of the 3 years (year 1: odds ratio [OR] = 0.74, 95% CI 0.60-0.91, p = 0.0044; year 2: OR = 0.53, 95% CI 0.42-0.66, p < 0.0001; year 3: OR = 0.61, 95% CI 0.48-0.77, p < 0.0001). This antifracture effect was persistent over 3 years, with the reductions in years 2 and 3 slightly larger than in year 1 (p = 0.097). This analysis shows that zoledronic acid offered significant protection from clinical fractures as early as 12 months. When administered annually, its beneficial effects persisted for at least 3 years.

Published
2012

9. Genetic variation in the RANKL/RANK/OPG signaling pathway is associated with bone turnover and bone mineral density in men

Author

Roshandel, Delnaz, primary, Holliday, Kate L, additional, Pye, Stephen R, additional, Boonen, Steven, additional, Borghs, Herman, additional, Vanderschueren, Dirk, additional, Huhtaniemi, Ilpo T, additional, Adams, Judith E, additional, Ward, Kate A, additional, Bartfai, Gyorgy, additional, Casanueva, Felipe, additional, Finn, Joseph D, additional, Forti, Gianni, additional, Giwercman, Aleksander, additional, Han, Thang S, additional, Kula, Krzysztof, additional, Lean, Michael E, additional, Pendleton, Neil, additional, Punab, Margus, additional, Silman, Alan J, additional, Wu, Frederick C, additional, Thomson, Wendy, additional, and O'Neill, Terence W, additional

Published
2010
Full Text
View/download PDF

14. Growth Without Growth Hormone Receptor: Estradiol Is a Major Growth Hormone-Independent Regulator of Hepatic IGF-I Synthesis

Author

Venken, Katrien, primary, Schuit, Frans, additional, Van Lommel, Leentje, additional, Tsukamoto, Katsura, additional, Kopchick, John J, additional, Coschigano, Karen, additional, Ohlsson, Claes, additional, Movérare, Sofia, additional, Boonen, Steven, additional, Bouillon, Roger, additional, and Vanderschueren, Dirk, additional

Published
2005
Full Text
View/download PDF

16. Evidence From Data Searches and Life-Table Analyses for Gender-Related Differences in Absolute Risk of Hip Fracture After Colles' or Spine Fracture: Colles' Fracture as an Early and Sensitive Marker of Skeletal Fragility in White Men

Author

Haentjens, Patrick, primary, Johnell, Olof, additional, Kanis, John A, additional, Bouillon, Roger, additional, Cooper, Cyrus, additional, Lamraski, Guyve, additional, Vanderschueren, Dirk, additional, Kaufman, Jean-Marc, additional, and Boonen, Steven, additional

Published
2004
Full Text
View/download PDF

19. Down-Regulation of the Serum Stimulatory Components of the Insulin-like Growth Factor (IGF) System (IGF-I, IGF-II, IGF Binding Protein [BP]-3, and IGFBP-5) in Age-Related (Type II) Femoral Neck Osteoporosis

Author

Boonen, Steven, primary, Mohan, Subburaman, additional, Dequeker, Jan, additional, Aerssens, Jeroen, additional, Vanderschueren, Dirk, additional, Verbeke, Geert, additional, Broos, Paul, additional, Bouillon, Roger, additional, and Baylink, David J., additional

Published
1999
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results